
Rayfel Schneider

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1742215/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Soluble Low-density Lipoprotein Receptor-related Protein 1 in Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2021, 48, 760-766.	2.0	0
2	Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‣abel, Randomized Study. Arthritis and Rheumatology, 2021, 73, 336-346.	5.6	23
3	Kawasaki Disease and Systemic Juvenile Idiopathic Arthritis – Two Ends of the Same Spectrum. Frontiers in Pediatrics, 2021, 9, 665815.	1.9	10
4	Clinical and psychosocial stress factors are associated with decline in physical activity over time in children with juvenile idiopathic arthritis. Pediatric Rheumatology, 2021, 19, 97.	2.1	8
5	Higher concentrations of vitamin D in Canadian children with juvenile idiopathic arthritis compared to healthy controls are associated with more frequent use of vitamin D supplements and season of birth. Nutrition Research, 2021, 92, 139-149.	2.9	5
6	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‣abel, Activeâ€Treatment Extension Study. Arthritis and Rheumatology, 2020, 72, 2147-2158.	5.6	21
7	"lt's Not Just About Getting Alongâ€, Exploring Learning Through the Discourse and Practice of Interprofessional Collaboration. Academic Medicine, 2020, 95, S73-S80.	1.6	9
8	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. Arthritis and Rheumatology, 2020, 72, 1945-1951.	5.6	28
9	Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. Rheumatology, 2020, 59, 2402-2411.	1.9	11
10	Physician practices for withdrawal of medications in inactive systemic juvenile arthritis, Childhood Arthritis and Rheumatology Research Alliance (CARRA) survey. Pediatric Rheumatology, 2019, 17, 48.	2.1	11
11	Emergent high fatality lung disease in systemic juvenile arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1722-1731.	0.9	122
12	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis. Arthritis Care and Research, 2019, 71, 703-716.	3.4	176
13	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‧ystemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis Care and Research, 2019, 71, 717-734.	3.4	225
14	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‧ystemic Polyarthritis, Sacroiliitis, and Enthesitis. Arthritis and Rheumatology, 2019, 71, 846-863.	5.6	110
15	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis–Associated Uveitis. Arthritis and Rheumatology, 2019, 71, 864-877.	5.6	57
16	Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2019, 46, 1117-1126.	2.0	13
17	OP0204â€EMAPALUMAB, AN INTERFERON GAMMA (IFN-Y)-BLOCKING MONOCLONAL ANTIBODY, IN PATIENTS WITH MACROPHAGE ACTIVATION SYNDROME (MAS) COMPLICATING SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA). , 2019, , .		15
18	Development of neoplasms in pediatric patients with rheumatic disease exposed to anti-tumor necrosis factor therapies: a single Centre retrospective study. Pediatric Rheumatology, 2018, 16, 17.	2.1	8

RAYFEL SCHNEIDER

#	Article	IF	CITATIONS
19	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. Pain, 2018, 159, 57-66.	4.2	29
20	A curious case of growth failure and hypercalcemia: Answers. Pediatric Nephrology, 2018, 33, 995-999.	1.7	1
21	A curious case of growth failure and hypercalcemia: Questions. Pediatric Nephrology, 2018, 33, 991-993.	1.7	3
22	Proposed Core Set of Items for Measuring Disease Activity in Systemic Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2018, 45, 115-121.	2.0	10
23	Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Annals of the Rheumatic Diseases, 2018, 77, 1710-1719.	0.9	79
24	Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology. Pediatric Rheumatology, 2018, 16, 45.	2.1	35
25	Systemic Juvenile Idiopathic Arthritis. Pediatric Clinics of North America, 2018, 65, 691-709.	1.8	86
26	Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clinical and Experimental Rheumatology, 2018, 36, 668-675.	0.8	31
27	Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Research and Therapy, 2017, 19, 13.	3.5	49
28	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Pediatric Rheumatology, 2017, 15, 68.	2.1	39
29	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology. 2016, 68, 566-576.	5.6	427
30	Efficacy of an Interinstitutional Mentoring Program Within Pediatric Rheumatology. Arthritis Care and Research, 2016, 68, 645-651.	3.4	9
31	The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010–2013. Journal of Rheumatology, 2016, 43, 1755-1762.	2.0	41
32	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2016, 75, 1092-1098.	0.9	72
33	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open, 2016, 2, e000161.	3.8	57
34	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 481-489.	0.9	338
35	Systemic onset juvenile idiopathic arthritis and exposure to fine particulate air pollution. Clinical and Experimental Rheumatology, 2016, 34, 946-952.	0.8	8
36	A case of pancreatitis, panniculitis and polyarthritis syndrome: Elucidating the pathophysiologic mechanisms of a rare condition. Journal of Pediatric Surgery Case Reports, 2015, 3, 223-226.	0.2	18

RAYFEL SCHNEIDER

#	Article	IF	CITATIONS
37	Don't let up: implementing and sustaining change in a new post-licensure education model for developing extended role practitioners involved in arthritis care. Journal of Multidisciplinary Healthcare, 2015, 8, 389.	2.7	8
38	The patient perspective: arthritis care provided by Advanced Clinician Practitioner in Arthritis Care program-trained clinicians. Open Access Rheumatology: Research and Reviews, 2015, 7, 45.	1.6	6
39	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Annals of the Rheumatic Diseases, 2015, 74, 1854-1860.	0.9	192
40	A177: Program Evaluation of the ACR/CARRA Inter-Institutional Mentoring Program (AMIGO) in Pediatric Rheumatology. Arthritis and Rheumatology, 2014, 66, S231-S231.	5.6	0
41	A170: Neoplasms in Pediatric Patients with Rheumatic Diseases Exposed to Biologics-A Quarternary Centre's Experience. Arthritis and Rheumatology, 2014, 66, S220-S221.	5.6	7
42	A56: Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Tocilizumab. Arthritis and Rheumatology, 2014, 66, S83.	5.6	14
43	AMIGO: A Novel Approach to the Mentorship Gap in PediatricÂRheumatology. Journal of Pediatrics, 2014, 164, 226-227.e3.	1.8	11
44	A145: Faculty and Resident Perceptions About Teaching and Learning the Pediatric Musculoskeletal Examination: An Exploratory Study. Arthritis and Rheumatology, 2014, 66, S188.	5.6	1
45	A141: Active Engagement of Teens with Juvenile Idiopathic Arthritis in Medical Education: What Do They Think Their Contribution Might Be?. Arthritis and Rheumatology, 2014, 66, S184-S184.	5.6	1
46	Juvenile rheumatoid arthritis. Rheumatic Disease Clinics of North America, 2002, 28, 503-530.	1.9	65
47	Early predictors of poor functional outcome in systemic-onset juvenile rheumatoid arthritis: A multicenter cohort study. Arthritis and Rheumatism, 2000, 43, 2402-2409.	6.7	124
48	The association between Turner's syndrome and juvenile rheumatoid arthritis. Pediatric Radiology, 1999, 29, 676-681.	2.0	34